BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shah MA, Janjigian YY, Stoller R, Shibata S, Kemeny M, Krishnamurthi S, Su YB, Ocean A, Capanu M, Mehrotra B, Ritch P, Henderson C, Kelsen DP. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. J Clin Oncol. 2015;33:3874-3879. [PMID: 26438119 DOI: 10.1200/jco.2015.60.7465] [Cited by in Crossref: 112] [Cited by in F6Publishing: 128] [Article Influence: 16.0] [Reference Citation Analysis]
Number Citing Articles
1 Manfredi S, Dior M, Bouche O, Barbier E, Hautefeuille V, Guillet M, Turpin J, Bourgeois V, Helene DO, Desgrippes R, Audemar F, Molin Y, Locher C, Chatellier T, Lecomte T, Baize N, Lecaille C, Spaeth D, Goujon G, Lepage C, Tougeron D; Metestomac Investigators/Collaborators. Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort. Cancer Med 2023;12:5341-51. [PMID: 36394147 DOI: 10.1002/cam4.5354] [Reference Citation Analysis]
2 Ostwal V, Ramaswamy A, Bhargava P, Srinivas S, Mandavkar S, Chaugule D, Peelay Z, Baheti A, Tandel H, Jadhav VK, Shinde S, Jadhav S, Gota V, Mittra I. A pro-oxidant combination of resveratrol and copper reduces chemotherapy-related non-haematological toxicities in advanced gastric cancer: results of a prospective open label phase II single-arm study (RESCU III study). Med Oncol 2022;40:17. [PMID: 36372825 DOI: 10.1007/s12032-022-01862-1] [Reference Citation Analysis]
3 Farrokhi P, Sadeghi A, Sharifi M, Riechelmann R, Moghaddas A. Efficacy and safety of FLOT regimen vs DCF, FOLFOX, and ECF regimens as perioperative chemotherapy treatments for resectable gastric cancer patients; a report from the middle east. Res Pharm Sci 2022;17:621-34. [PMID: 36704436 DOI: 10.4103/1735-5362.359430] [Reference Citation Analysis]
4 Zhao X, Liu X, Li W, Qiu L, Huang M, Wang C, Chen Z, Zhang W, Feng W, Guo W, Zhu X. Randomized phase II study of TX followed by XELOX versus the reverse sequence for chemo-naive patients with metastatic gastric cancer. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.911160] [Reference Citation Analysis]
5 Ramaswamy A, Bhargava P, Srinivas S, Kannan S, Bhandare M, Chaudhari V, Mantri A, Kapoor A, Das S, Booma N, Chaugule D, Shrikhande SV, Ostwal V. Perioperative Modified FLOT Versus EOX in Locally Advanced Resectable Gastric and Gastro-Oesophageal Junction Adenocarcinoma: Results of a Matched-Pair Analysis. J Gastrointest Cancer 2022. [PMID: 36242748 DOI: 10.1007/s12029-022-00867-3] [Reference Citation Analysis]
6 Li Y, Xu C, Wang B, Xu F, Ma F, Qu Y, Jiang D, Li K, Feng J, Tian S, Wu X, Wang Y, Liu Y, Qin Z, Liu Y, Qin J, Song Q, Zhang X, Sujie A, Huang J, Liu T, Shen K, Zhao JY, Hou Y, Ding C. Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals new therapeutic strategies. Nat Commun 2022;13:5723. [PMID: 36175412 DOI: 10.1038/s41467-022-33282-0] [Reference Citation Analysis]
7 Nguyen HT, Do KH, Le NB, Tran T. Treatment Outcome and Safety of the TCX Regimen for Advanced Gastric Cancer: A Prospective Cohort Study. Cancer Manag Res 2022;14:2825-37. [PMID: 36164467 DOI: 10.2147/CMAR.S384325] [Reference Citation Analysis]
8 . Stomach (Gastric) Cancer. Fundamentals of Cancer Detection, Treatment, and Prevention 2022. [DOI: 10.1002/9783527838561.ch17] [Reference Citation Analysis]
9 Grave A, Blanc J, De Bari B, Pernot M, Boulbair F, Noirclerc M, Vienot A, Kim S, Borg C, Boustani J. Long-Term Disease Control After locoregional Pelvic Chemoradiation in Patients with Advanced Anal Squamous Cell Carcinoma. Front Oncol 2022;12:918271. [DOI: 10.3389/fonc.2022.918271] [Reference Citation Analysis]
10 Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, Vogel A, Smyth E. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology 2022. [DOI: 10.1016/j.annonc.2022.07.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
11 Möhring C, Timotheou A, Mańczak A, Sadeghlar F, Zhou T, Mahn R, Bartels A, Monin M, Toma M, Feldmann G, Brossart P, Köksal M, Sarria GR, Giordano FA, Lingohr P, Jafari A, Kalff JC, Strassburg CP, Gonzalez-Carmona MA. Efficacy and tolerability of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in unselected patients with advanced gastric and gastroesophageal cancer: does age really matter? J Cancer Res Clin Oncol 2022. [PMID: 35763109 DOI: 10.1007/s00432-022-04109-8] [Reference Citation Analysis]
12 Boisteau E, François E, Aparicio T, Le Malicot K, Boulahssass R, Lecomte T, Laurent-Puig P, Guiu B, Paillaud E, Galais MP, Lopez-Trabada Ataz D, Tougeron D, Dourthe LM, Guimbaud R, Samalin E, Moreau M, Louvet C, Lepage C, Lièvre A. SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer. Dig Liver Dis 2022;54:747-54. [PMID: 35351371 DOI: 10.1016/j.dld.2022.03.001] [Reference Citation Analysis]
13 Orillard E, Henriques J, Vernerey D, Almotlak H, Calcagno F, Fein F, Fratté S, Jary M, Klajer E, Vienot A, Borg C, Kim S. Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients. Front Oncol 2022;12:763926. [PMID: 35340264 DOI: 10.3389/fonc.2022.763926] [Reference Citation Analysis]
14 Bhargava P, Das S, Ostwal V, Srinivas S, Bhandare M, Chaudhari V, Bal M, Mantri A, Kapoor A, Shrikhande SV, Ramaswamy A. An Analysis of Tolerance and Early Survival Outcomes with Perioperative Modified FLOT in Gastric Cancers. South Asian J Cancer. [DOI: 10.1055/s-0041-1733349] [Reference Citation Analysis]
15 Srinivasalu VK, Philip A, Pillai R, Jose WM, Keechilat P. A Prospective Study to Evaluate the Efficacy of the Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Chemotherapy Regimen in Patients with Locally Advanced and Metastatic Adenocarcinoma of Stomach. Indian J Med Paediatr Oncol. [DOI: 10.1055/s-0042-1742445] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Arslan C, Atilla FD. Modified docetaxel, cisplatin, and 5-fluorouracil combination regimen and capecitabine maintenance in metastatic gastric cancer: toxicity and efficacy results. Support Care Cancer 2022. [PMID: 35106659 DOI: 10.1007/s00520-022-06859-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Besova NS, Kalinin AE, Nered SN, Triakin AA, Gamaiunov SV, Kozlov NA, Stilidi IS, Karachun AM, Kononets PV, Malikhova OA, Riabov AB, Khomiakov VM, Fedenko AA, Bolotina LV, Falaleeva NA, Nevol'skikh AA, Ivanov SA, Khailova ZV, Gevorkian TG, Butenko AV, Gil'mutdinova IR, Eremushkin MA, Ivanova GE, Kondrat'eva KO, Konchugova TV, Krutov AA, Obukhova OA, Semiglazova TI, Filonenko EV, Khulamkhanova MM, Romanov AI. Gastric cancer: Russian clinical guidelines. J Mod Onco 2021;23:541-571. [DOI: 10.26442/18151434.2021.4.201239] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Li S, Luk HY, Xia C, Chen Z, Chan PKS, Boon SS. Oesophageal carcinoma: The prevalence of DNA tumour viruses and therapy. Tumour Virus Res 2021;13:200231. [PMID: 34920177 DOI: 10.1016/j.tvr.2021.200231] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Zheng SH, Liu SR, Wang HB, Wei YH, Li H, Wang GN, Huang ZL, Ding SR, Chen C, Tao YL, Li XH, Glorieux C, Huang P, Wu YF, Xia YF. Treatment and Survival Outcomes Associated With Platinum Plus Low-Dose, Long-term Fluorouracil for Metastatic Nasopharyngeal Carcinoma. JAMA Netw Open 2021;4:e2138444. [PMID: 34902036 DOI: 10.1001/jamanetworkopen.2021.38444] [Reference Citation Analysis]
20 Wu L, Feng Y, Wu Z, Xu H, Zhang C, Ning J, Wang R, Chen J, Xie M, Zhang Y, Bu L, Hao J, Ma T. Survival outcomes of adjuvant taxanes, platinum plus fluoropyrimidines versus platinum and fluoropyrimidines for gastric cancer patients after D2 gastrectomy: a retrospective propensity score-matched analysis. World J Surg Oncol 2021;19:272. [PMID: 34507562 DOI: 10.1186/s12957-021-02390-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Petersen PC, Petersen LN, Vogelius I, Bjerregaard JK, Baeksgaard L. A randomized phase 2 trial of first-line docetaxel, carboplatin, capecitabine (CTX) and epirubicin, oxaliplatin, capecitabine (EOX) in advanced esophagogastric adenocarcinoma. Acta Oncol 2021;60:948-53. [PMID: 34086514 DOI: 10.1080/0284186X.2021.1928281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Deleporte A, Van den Eynde M, Forget F, Holbrechts S, Delaunoit T, Houbiers G, Kalantari HR, Laurent S, Vanderstraeten E, De Man M, Vergauwe P, Clausse M, Van Der Auwera J, D'Hondt L, Pierre P, Ghillemijn B, Covas A, Paesmans M, Ameye L, Awada A, Sclafani F, Hendlisz A. Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study. Cancer Med 2021;10:4366-74. [PMID: 34057299 DOI: 10.1002/cam4.3976] [Reference Citation Analysis]
23 Acikgoz Y, Aktürk Esen S, Ucar G, Dirikoc M, Ergun Y, Bal O, Uncu D. The Comparison of mDCF and mFOLFOX-6 as First-Line Treatment in Metastatic Gastric Cancer. Cureus 2021;13:e14882. [PMID: 34104608 DOI: 10.7759/cureus.14882] [Reference Citation Analysis]
24 Evrard C, Louvet C, Hajbi FE, Fiore FD, Malicot KL, Aparicio T, Bouché O, Laurent-Puig P, Bibeau F, Lecomte T, Lièvre A, Guimbaud R, Kim S, Zaanan A, Sokol H, Chibaudel B, Desrame J, Pierre S, Gonzalez D, Lepage C, Tougeron D. PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer. Dig Liver Dis 2021;53:420-6. [PMID: 33358124 DOI: 10.1016/j.dld.2020.11.036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
25 Onitilo AA, Stankowski-Drengler TJ, Shiyanbola O, Engel J, Tanimu S, Fagbemi SO, Li YH. Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) as a Neoadjuvant Chemotherapy for Non-metastatic Esophageal Cancer (nMEC). Clin Med Res 2021;19:64-71. [PMID: 33789952 DOI: 10.3121/cmr.2021.1573] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Guercio BJ, Iyer G, Kidwai WZ, Lacouture ME, Ghafoor S, Rossi AM, Assis DN, Chen YB, Busam KJ, Janjigian YY, Jhaveri K, Feldman DR, Capozzi A, Figueroa V, Bajorin DF, Rosenberg JE, Hollmann TJ, Funt SA. Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report. Case Rep Oncol 2021;14:430-8. [PMID: 33790764 DOI: 10.1159/000514345] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
27 Rocha-Filho DR, Peixoto RD, Weschenfelder RF, Rego JFM, Riechelmann R, Coutinho AK, Fernandes GS, Jacome AA, Andrade AC, Murad AM, Mello CAL, Miguel DSCG, Gomes DBD, Racy DJ, Moraes ED, Akaishi EH, Carvalho ES, Mello ES, Filho FM, Coimbra FJF, Capareli FC, Arruda FF, Vieira FMAC, Takeda FR, Cotti GCC, Pereira GLS, Paulo GA, Ribeiro HSC, Lourenco LG, Crosara M, Toneto MG, Oliveira MB, de Lourdes Oliveira M, Begnami MD, Forones NM, Yagi O, Ashton-Prolla P, Aguillar PB, Amaral PCG, Hoff PM, Araujo RLC, Di Paula Filho RP, Gansl RC, Gil RA, Pfiffer TEF, Souza T, Ribeiro U Jr, Jesus VHF, Costa WL Jr, Prolla G. Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of oesophageal cancer. Ecancermedicalscience 2021;15:1195. [PMID: 33889204 DOI: 10.3332/ecancer.2021.1195] [Reference Citation Analysis]
28 Farrokhi P, Sadeghi A, sharifi M, Dadvand P, Riechelmann R, Moghaddas A. Efficacy and Safety of FLOT regimen vs DCF, FOLFOX, and ECF regimens as Perioperative Chemotherapy Treatments for Resectable Gastric Cancer Patients.. [DOI: 10.1101/2021.01.26.21250550] [Reference Citation Analysis]
29 Park H, Jin RU, Wang-Gillam A, Suresh R, Rigden C, Amin M, Tan BR, Pedersen KS, Lim KH, Trikalinos NA, Acharya A, Copsey ML, Navo KA, Morton AE, Gao F, Lockhart AC. FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol 2020;6:1231-40. [PMID: 32469386 DOI: 10.1001/jamaoncol.2020.2020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
30 Torres JA, de Jesus VHF. Circulating Tumor Cells in Gastric Cancer. Atlas of Liquid Biopsy 2021. [DOI: 10.1007/978-3-030-69879-9_7] [Reference Citation Analysis]
31 De Vita F, Tirino G, Pompella L, Petrillo A. Gastric Cancer: Advanced/Metastatic Disease. Practical Medical Oncology Textbook 2021. [DOI: 10.1007/978-3-030-56051-5_36] [Reference Citation Analysis]
32 Jimenez-Fonseca P, Carmona-Bayonas A, Martínez de Castro E, Custodio A, Pericay Pijaume C, Hernandez R, Aguado G, Castro Unanua N, Cano JM, López F, Garrido M, Fernández Montes A, Visa L, Sánchez Cánovas M, Limón ML, Martínez Lago N, Pimentel P, Hurtado A, Azkárate A, Longo F, Diez M, Arias-Martinez A, Sauri T, Martín Carnicero A, Mangas M, Martín Richard M, Granja M, Ramchandani A, Hernández Pérez C, Cerdá P, Gil-Negrete A, Calvo M, Vidal Tocino R, Gallego J. External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit? Gastric Cancer 2021;24:445-56. [PMID: 32970266 DOI: 10.1007/s10120-020-01116-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
33 Bartels P, Thuss-patience P. Inductive Preoperative Chemotherapy for Peritoneal Metastases of Tumors of the Upper GI Tract. Peritoneal Tumors and Metastases 2021. [DOI: 10.1007/978-3-030-62640-2_7] [Reference Citation Analysis]
34 Titova TA, Besova NS, Artamonova EA. A case of effective disease control of advanced gastric cancer following ramucirumab plus FOLFIRI in second line treatment in clinical practice. Medicinskij sovet 2020. [DOI: 10.21518/2079-701x-2020-20-201-206] [Reference Citation Analysis]
35 Alhames S, Hsu A, Rustam F, Kassar R, Shihade MB, Almhanna K. Esophageal cancer in Aleppo, Syria 2010-2020: a rare cancer in a war zone. Ann Transl Med 2020;8:1105. [PMID: 33145324 DOI: 10.21037/atm-20-4474] [Reference Citation Analysis]
36 Epistola RJ, Chao J. Systemic therapy for advanced gastroesophageal cancers: progress and pitfalls. Transl Gastroenterol Hepatol 2020;5:53. [PMID: 33073048 DOI: 10.21037/tgh.2020.01.10] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
37 Parisi A, Porzio G, Ficorella C. Multimodality Treatment in Metastatic Gastric Cancer: From Past to Next Future. Cancers (Basel) 2020;12:E2598. [PMID: 32932914 DOI: 10.3390/cancers12092598] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
38 Hsu A, Zayac AS, Eturi A, Almhanna K. Treatment for metastatic adenocarcinoma of the stomach and gastroesophageal junction: 2020. Ann Transl Med 2020;8:1109. [PMID: 33145328 DOI: 10.21037/atm-20-1159] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
39 Jiang H, Zheng Y, Qian J, Mao C, Xu X, Li N, Xiao C, Wang H, Teng L, Zhou H, Wang S, Zhu D, Peng B, Shen L, Xu N. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial. BMC Cancer 2020;20:760. [PMID: 32795349 DOI: 10.1186/s12885-020-07251-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
40 Besova NS, Titova TA, Artamonova ЕV, Tryakin AA, Stroyakovskiy DL, Perminova EV, Yukalchuk DY, Ponomarenko DM, Belyak NP, Orlova RV, Teletaeva GM, Ratner EY, Mochalova AS, Gordeeva OO, Zhabina AS, Gamayunov SV, Smolin AV, Povyshev AY, Andrievskikh MI, Stilidi IS. Analysis of prognostic factors for survival in the Russian population of patients with disseminated gastric cancer, who received ramucirumab as secondline therapy in the RAMSELGA trial. Medicinskij sovet 2020. [DOI: 10.21518/2079-701x-2020-9-165-174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Shah MA, Enzinger P, Ko AH, Ocean AJ, Philip PA, Thakkar PV, Cleveland K, Lu Y, Kortmansky J, Christos PJ, Zhang C, Kaur N, Elmonshed D, Galletti G, Sarkar S, Bhinder B, Pittman ME, Plotnikova OM, Kotlov N, Frenkel F, Bagaev A, Elemento O, Betel D, Giannakakou P, Lenz HJ. Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome. Clin Cancer Res 2020;26:4756-66. [PMID: 32641434 DOI: 10.1158/1078-0432.CCR-19-3920] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
42 Chen GM, Yuan SQ, Nie RC, Luo TQ, Jiang KM, Liang CC, Li YF, Zhang DY, Yu JH, Hou F, Wang Y, Chen YB. Surgical Outcome and Long-Term Survival of Conversion Surgery for Advanced Gastric Cancer. Ann Surg Oncol 2020;27:4250-60. [PMID: 32506192 DOI: 10.1245/s10434-020-08559-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
43 Morales ASR, Joy JK, Zbona DM. Administration sequence for multi-agent oncolytic regimens. J Oncol Pharm Pract 2020;26:933-942. [DOI: 10.1177/1078155219895070] [Reference Citation Analysis]
44 Arai H, Nakajima TE. Recent Developments of Systemic Chemotherapy for Gastric Cancer. Cancers (Basel) 2020;12:E1100. [PMID: 32354119 DOI: 10.3390/cancers12051100] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
45 Ahmadzadeh A, Seyedian SS, Valizadeh A, Soleimani M, Nazari P, Hamidi H. The Efficacy and Safety of Modified Docetaxel, Cisplatin, and 5-Fluorouracil Vs. Epirubicin, Oxaliplatin, and Capecitabine Regimen in the Advanced Gastric Cancer: A Randomized Controlled Clinical Trial. Asian Pac J Cancer Prev 2020;21:727-32. [PMID: 32212800 DOI: 10.31557/APJCP.2020.21.3.727] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
46 Ferrari D, Ghi MG, Franzese C, Codecà C, Gau M, Fayette J. The Slippery Role of Induction Chemotherapy in Head and Neck Cancer: Myth and Reality. Front Oncol 2020;10:7. [PMID: 32038985 DOI: 10.3389/fonc.2020.00007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
47 Ku GY, Ilson DH. Cancer of the Esophagus. Abeloff's Clinical Oncology 2020. [DOI: 10.1016/b978-0-323-47674-4.00071-2] [Reference Citation Analysis]
48 Ku GY, Ilson DH. Cancer of the Stomach. Abeloff's Clinical Oncology 2020. [DOI: 10.1016/b978-0-323-47674-4.00072-4] [Reference Citation Analysis]
49 Brar G, Shah MA. The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma. Therap Adv Gastroenterol 2019;12:1756284819869767. [PMID: 31516556 DOI: 10.1177/1756284819869767] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
50 Ngai LL, Ter Veer E, van den Boorn HG, van Herk EH, van Kleef JJ, van Oijen MGH, van Laarhoven HWM. TOXview: a novel graphical presentation of cancer treatment toxicity profiles. Acta Oncol 2019;58:1138-48. [PMID: 31017020 DOI: 10.1080/0284186X.2019.1601256] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
51 Parisi A, Cortellini A, Roberto M, Venditti O, Santini D, Dell'Aquila E, Stellato M, Marchetti P, Occhipinti MA, Zoratto F, Mazzuca F, Tinari N, De Tursi M, Iezzi L, Natoli C, Ratti M, Pizzo C, Ghidini M, Porzio G, Ficorella C, Cannita K. Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study. J Cancer Res Clin Oncol 2019;145:2365-73. [PMID: 31280347 DOI: 10.1007/s00432-019-02971-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
52 Zhang D, Wu JR, Duan XJ, Wang KH, Zhao Y, Ni MW, Liu SY, Zhang XM, Zhang B. A Bayesian Network Meta-Analysis for Identifying the Optimal Taxane-Based Chemotherapy Regimens for Treating Gastric Cancer. Front Pharmacol 2019;10:717. [PMID: 31333452 DOI: 10.3389/fphar.2019.00717] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
53 Schokker S, van der Woude SO, van Kleef JJ, van Zoen DJ, van Oijen MGH, Mearadji B, Beenen LFM, Stroes CI, Waasdorp C, Jibodh RA, Creemers A, Meijer SL, Hooijer GKJ, Punt CJA, Bijlsma MF, van Laarhoven HWM. Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study). Cancers (Basel) 2019;11:E827. [PMID: 31207904 DOI: 10.3390/cancers11060827] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
54 Rosenberg AJ, Rademaker A, Hochster HS, Ryan T, Hensing T, Shankaran V, Baddi L, Mahalingam D, Mulcahy MF, Benson AB 3rd. Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up. Oncologist 2019;24:1039-e642. [PMID: 31138725 DOI: 10.1634/theoncologist.2019-0330] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
55 McCoach CE, Bivona TG. Engineering Multidimensional Evolutionary Forces to Combat Cancer. Cancer Discov 2019;9:587-604. [PMID: 30992280 DOI: 10.1158/2159-8290.CD-18-1196] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
56 Li B, Chen L, Luo HL, Yi FM, Wei YP, Zhang WX. Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: A systematic review and meta-analysis. World J Clin Cases 2019; 7(5): 600-615 [PMID: 30863759 DOI: 10.12998/wjcc.v7.i5.600] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
57 Mondaca S, Margolis M, Sanchez-Vega F, Jonsson P, Riches JC, Ku GY, Hechtman JF, Tuvy Y, Berger MF, Shah MA, Kelsen DP, Ilson DH, Yu K, Goldberg Z, Epstein AS, Desai A, Chung V, Chou JF, Capanu M, Solit DB, Schultz N, Janjigian YY. Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer. Gastric Cancer 2019;22:355-62. [PMID: 30088161 DOI: 10.1007/s10120-018-0861-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
58 Klempner SJ, Maron SB, Chase L, Lomnicki S, Wainberg ZA, Catenacci DVT. Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis. Oncologist 2019;24:475-82. [PMID: 30470690 DOI: 10.1634/theoncologist.2018-0602] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
59 Mondaca S, Chatila WK, Bates D, Hechtman JF, Cercek A, Segal NH, Stadler ZK, Varghese AM, Kundra R, Capanu M, Shia J, Schultz N, Saltz L, Yaeger R. FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer. Clin Colorectal Cancer 2019;18:e39-52. [PMID: 30316684 DOI: 10.1016/j.clcc.2018.09.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
60 Kim HS, Ryu MH, Zang DY, Park SR, Han B, Kang WK, Rha SY, Jung M, Kim JS, Kang BW, Lee KH, Rho SY, Kim JH, Kim KC, Cho JW, Choi DR, Lim H, Kang HS, Soh JS, Kim MJ, Seo J, Kang YK. Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11. Gastric Cancer 2018;21:802-10. [PMID: 29372461 DOI: 10.1007/s10120-018-0794-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
61 Harada K, Lopez A, Shanbhag N, Badgwell B, Baba H, Ajani J. Recent advances in the management of gastric adenocarcinoma patients. F1000Res 2018;7:F1000 Faculty Rev-1365. [PMID: 30228868 DOI: 10.12688/f1000research.15133.1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
62 McGee SF, AlGhareeb W, Ahmad CH, Armstrong D, Babak S, Berry S, Biagi J, Booth C, Bossé D, Champion P, Colwell B, Finn N, Goel R, Gray S, Green J, Harb M, Hyde A, Jeyakumar A, Jonker D, Kanagaratnam S, Kavan P, MacMillan A, Muinuddin A, Patil N, Porter G, Powell E, Ramjeesingh R, Raza M, Rorke S, Seal M, Servidio-Italiano F, Siddiqui J, Simms J, Smithson L, Snow S, St-Hilaire E, Stuckless T, Tate A, Tehfe M, Thirlwell M, Tsvetkova E, Valdes M, Vickers M, Virik K, Welch S, Marginean C, Asmis T. Eastern Canadian Colorectal Cancer Consensus Conference 2017. Curr Oncol 2018;25:262-74. [PMID: 30111967 DOI: 10.3747/co.25.4083] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
63 Zaanan A, Bouché O, Benhaim L, Buecher B, Chapelle N, Dubreuil O, Fares N, Granger V, Lefort C, Gagniere J, Meilleroux J, Baumann AS, Vendrely V, Ducreux M, Michel P; Thésaurus National de Cancérologie Digestive (TNCD). Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Dig Liver Dis 2018;50:768-79. [PMID: 29886081 DOI: 10.1016/j.dld.2018.04.025] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 10.0] [Reference Citation Analysis]
64 Akiyama Y, Sasaki A, Endo F, Nikai H, Amano S, Umemura A, Baba S, Chiba T, Kimura T, Takahara T, Nitta H, Otsuka K, Mizuno M, Kimura Y, Koeda K, Iwaya T. Outcomes of esophagectomy after chemotherapy with biweekly docetaxel plus cisplatin and fluorouracil for advanced esophageal cancer: a retrospective cohort analysis. World J Surg Oncol 2018;16:122. [PMID: 29966526 DOI: 10.1186/s12957-018-1420-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
65 Harada K, Baba H, Ajani JA. Recent trend in gastric cancer treatment in the USA. J Cancer Metastasis Treat 2018;4:18. [PMID: 34113719 DOI: 10.20517/2394-4722.2017.74] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
66 Bruera G, Massacese S, Galvano A, Mas AD, Guadagni S, Calvisi G, Ciacco E, Russo A, Ricevuto E; Oncology Network ASL1 Abruzzo, Italy. Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer. Oncotarget 2018;9:20339-50. [PMID: 29755655 DOI: 10.18632/oncotarget.24861] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
67 Zaanan A, Samalin E, Aparicio T, Bouche O, Laurent-Puig P, Manfredi S, Michel P, Monterymard C, Moreau M, Rougier P, Tougeron D, Taieb J, Louvet C. Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study). Dig Liver Dis 2018;50:408-10. [PMID: 29409778 DOI: 10.1016/j.dld.2018.01.119] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
68 Wan J, Xu S, Wu Y, Wu B, Liao DJ, Xu N, Wang G. Management and survival analysis of elderly patients with a cancer in the digestive system who refused to receive anticancer treatments. Support Care Cancer 2018;26:2333-9. [PMID: 29417291 DOI: 10.1007/s00520-018-4065-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
69 Lopez A, Harada K, Mizrak Kaya D, Ajani JA. Current therapeutic landscape for advanced gastroesophageal cancers. Ann Transl Med 2018;6:78. [PMID: 29666801 DOI: 10.21037/atm.2017.10.29] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
70 Zhang PF, Sheng LL, Wang G, Tian M, Zhu LY, Zhang R, Zhang J, Zhu JS. miR-363 promotes proliferation and chemo-resistance of human gastric cancer via targeting of FBW7 ubiquitin ligase expression. Oncotarget. 2016;7:35284-35292. [PMID: 27167197 DOI: 10.18632/oncotarget.9169] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 8.4] [Reference Citation Analysis]
71 Fayette J, Fontaine-Delaruelle C, Ambrun A, Daveau C, Poupart M, Ramade A, Zrounba P, Neidhardt EM, Péron J, Diallo A, Céruse P. Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients. Oncotarget 2016;7:37297-304. [PMID: 27119503 DOI: 10.18632/oncotarget.8934] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
72 Thuss-patience P. Induktive präoperative Chemotherapie bei peritonealen Metastasen von Tumoren des oberen GI-Trakts. Peritoneale Tumoren und Metastasen 2018. [DOI: 10.1007/978-3-662-54500-3_7] [Reference Citation Analysis]
73 Ilson DH, van Hillegersberg R. Management of Patients With Adenocarcinoma or Squamous Cancer of the Esophagus. Gastroenterology 2018;154:437-51. [PMID: 29037469 DOI: 10.1053/j.gastro.2017.09.048] [Cited by in Crossref: 55] [Cited by in F6Publishing: 58] [Article Influence: 11.0] [Reference Citation Analysis]
74 Kawamoto Y, Komatsu Y, Yuki S, Sawada K, Muranaka T, Harada K, Nakatsumi H, Fukushima H, Ishiguro A, Dazai M, Hatanaka K, Nakamura M, Iwanaga I, Uebayashi M, Sogabe S, Kobayashi Y, Miyagishima T, Ono K, Sakamoto N, Sakata Y. Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer. BMC Cancer 2017;17:837. [PMID: 29221445 DOI: 10.1186/s12885-017-3850-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
75 Janmaat VT, Steyerberg EW, van der Gaast A, Mathijssen RH, Bruno MJ, Peppelenbosch MP, Kuipers EJ, Spaander MC. Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer. Cochrane Database Syst Rev. 2017;11:CD004063. [PMID: 29182797 DOI: 10.1002/14651858.cd004063.pub4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 44] [Article Influence: 4.2] [Reference Citation Analysis]
76 Fontana E, Smyth EC, Cunningham D. Esophagogastric Adenocarcinoma: Is More Chemotherapy Better? Curr Treat Options Oncol 2016;17:21. [PMID: 27032643 DOI: 10.1007/s11864-016-0395-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
77 Quadri HS, Smaglo BG, Morales SJ, Phillips AC, Martin AD, Chalhoub WM, Haddad NG, Unger KR, Levy AD, Al-Refaie WB. Gastric Adenocarcinoma: A Multimodal Approach.Front Surg. 2017;4:42. [PMID: 28824918 DOI: 10.3389/fsurg.2017.00042] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
78 Smyth EC, Lagergren J, Fitzgerald RC, Lordick F, Shah MA, Lagergren P, Cunningham D. Oesophageal cancer. Nat Rev Dis Primers 2017;3:17048. [PMID: 28748917 DOI: 10.1038/nrdp.2017.48] [Cited by in Crossref: 457] [Cited by in F6Publishing: 483] [Article Influence: 76.2] [Reference Citation Analysis]
79 Salati M, Di Emidio K, Tarantino V, Cascinu S. Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer? ESMO Open 2017;2:e000206. [PMID: 29209523 DOI: 10.1136/esmoopen-2017-000206] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
80 Mizrak Kaya D, Harada K, Ajani JA. Advances in therapeutic options for esophageal and esophagogastric junctional adenocarcinoma. Expert Opinion on Orphan Drugs 2017;5:549-557. [DOI: 10.1080/21678707.2017.1330146] [Reference Citation Analysis]
81 Wu FL, Zhang J, Li W, Bian BX, Hong YD, Song ZY, Wang HY, Cui FB, Li RT, Liu Q, Jiang XD, Li XM, Zheng JN. Enhanced antiproliferative activity of antibody-functionalized polymeric nanoparticles for targeted delivery of anti-miR-21 to HER2 positive gastric cancer. Oncotarget 2017;8:67189-202. [PMID: 28978026 DOI: 10.18632/oncotarget.18066] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
82 Law AM, Lim E, Ormandy CJ, Gallego-Ortega D. The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy. Endocr Relat Cancer 2017;24:R123-44. [PMID: 28193698 DOI: 10.1530/ERC-16-0404] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 7.8] [Reference Citation Analysis]
83 Andrikou K, Salati M, Fontana A, Spallanzani A, Pipitone S, Gelsomino F, Barbolini M, Cascinu S. Advanced gastric cancer: is there an optimal chemotherapy regimen? Expert Review of Quality of Life in Cancer Care 2017;2:123-132. [DOI: 10.1080/23809000.2017.1313683] [Reference Citation Analysis]
84 Maeda O, Matsuoka A, Miyahara R, Funasaka K, Hirooka Y, Fukaya M, Nagino M, Kodera Y, Goto H, Ando Y. Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study. World J Gastroenterol 2017; 23(6): 1090-1097 [PMID: 28246483 DOI: 10.3748/wjg.v23.i6.1090] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
85 Ochenduszko S, Puskulluoglu M, Konopka K, Fijorek K, Slowik AJ, Pędziwiatr M, Budzyński A. Clinical effectiveness and toxicity of second-line irinotecan in advanced gastric and gastroesophageal junction adenocarcinoma: a single-center observational study. Ther Adv Med Oncol 2017;9:223-33. [PMID: 28491144 DOI: 10.1177/1758834016689029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
86 Xie X, Wu Y, Luo Sh, Yang H, Li L, Zhou S, Shen R, Lin H. Efficacy and Toxicity of Low-Dose versus Conventional-Dose Chemotherapy for Malignant Tumors: a Meta-Analysis of 6 Randomized Controlled Trials. Asian Pac J Cancer Prev 2017;18:479-84. [PMID: 28345833 DOI: 10.22034/APJCP.2017.18.2.479] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
87 Thuss-patience P. Palliative Chemotherapie: Standard und Individualisierung des Magen- und Kardiakarzinoms. Moderne Chirurgie des Magen- und Kardiakarzinoms 2017. [DOI: 10.1007/978-3-662-53188-4_8] [Reference Citation Analysis]
88 Pfeiffer P, Qvortrup C, Krogh M, Schoennemann K, Vestermark LW, Jensen HA, Bjerregaard JK. S-1 in combination with docetaxel and oxaliplatin in patients with advanced gastro-esophageal adenocarcinoma: two parallel phase 1/2a studies. Acta Oncol 2017;56:46-51. [PMID: 27911128 DOI: 10.1080/0284186X.2016.1257865] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
89 Cheng Y, Yang B, Xi Y, Chen X. RAD51B as a potential biomarker for early detection and poor prognostic evaluation contributes to tumorigenesis of gastric cancer. Tumour Biol 2016;37:14969-78. [PMID: 27651161 DOI: 10.1007/s13277-016-5340-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
90 de Mestier L, Lardière-Deguelte S, Volet J, Kianmanesh R, Bouché O. Recent insights in the therapeutic management of patients with gastric cancer. Dig Liver Dis 2016;48:984-94. [PMID: 27156069 DOI: 10.1016/j.dld.2016.04.010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
91 Kiesewetter B, Raderer M, Steger GG, Bartsch R, Pirker R, Zöchbauer-Müller S, Prager G, Krainer M, Preusser M, Schmidinger M, Zielinski CC. The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. ESMO Open 2016;1:e000066. [PMID: 27843624 DOI: 10.1136/esmoopen-2016-000066] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
92 Mikhail S. "Does the Punishment Fit the Crime?". J Clin Oncol 2016;34:2067-8. [PMID: 26976411 DOI: 10.1200/JCO.2015.65.8492] [Reference Citation Analysis]
93 Lorenzen S, Lordick F. Fortgeschrittenes Magenkarzinom. Onkologe 2016;22:406-412. [DOI: 10.1007/s00761-016-0028-2] [Reference Citation Analysis]
94 Romero D. mDCF--new standard-of-care? Nat Rev Clin Oncol 2015;12:686. [PMID: 26483295 DOI: 10.1038/nrclinonc.2015.188] [Reference Citation Analysis]